CHENGZHI(SZ:000990) Huan Qiu Wang·2025-05-28 11:22Core Insights - The NHNE China International Health Nutrition Expo held in Guangzhou from May 21 to 23, 2025, attracted over 1,200 participating companies and more than 100,000 professional attendees [1] - The product "Libos® D-Ribose Powder" by Chengzhi Life Science Technology Co., Ltd. is the first approved health food in China featuring D-Ribose as the main active ingredient, known for its dual functions of anti-fatigue and hypoxia resistance, and is making significant changes in cardiac protection [1][3] Company Development - Chengzhi Life Science Technology Co., Ltd. has been tracking nearly 300,000 effective data points in China, showing that D-Ribose improves various cardiac symptoms [6] - The company has established collaborations with Tsinghua University and Beijing Sport University to conduct clinical studies on D-Ribose's application in athletics, demonstrating its benefits in enhancing anaerobic thresholds and reducing muscle damage markers [8] - The brand "Libos" was recently recognized as the leading brand in D-Ribose products in China, with a brand awareness rate of 98.12% [8][9] Market Performance - In 2024, sales of Libos® D-Ribose Powder increased by approximately 50%, with single product sales exceeding 100 million yuan, making it a standout in its category [9] - The company has shifted its strategy from being a raw material supplier to actively engaging with consumers and promoting brand recognition [11] Industry Trends - Cardiovascular diseases remain the leading cause of death globally, with the number of deaths rising from 270 million to 540 million over the past 30 years [13] - Chengzhi Life Science aims to focus on nutritional intervention for cardiovascular disease management, leveraging D-Ribose's role in energy metabolism and mitochondrial protection [15][16] Future Strategy - The company plans to enhance brand building and develop new health products with clear mechanisms of action and sufficient clinical research to contribute to the Healthy China 2030 initiative [17]